Investor Relations

Deciphera Pharmaceuticals (DCPH) is a biopharmaceutical company focused on discovering, developing, and delivering important new medicines to patients for the treatment of cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to execute our strategy to develop a broad portfolio of innovative medicines. We have one approved drug, QINLOCK®, and we are developing two clinical-stage drug candidates. In addition, our drug discovery teams are working on new targets to develop the next generation of cancer medicines.

Deciphera

Press Releases

Latest Presentation

Latest ESG Report

Events and Presentations

Price

Change

52 Week High

Copyright West LLC. Minimum 15 minutes delayed.

more details